Abstract
This pilot randomized controlled clinical trial of patients with ARDS was implemented to study the impact of inhaled nitric oxide (inhNO) on lung function, morbidity, and mortality. Thirty patients with ARDS were randomly allocated to usual care or usual care plus inhNO. The optimal dose of inhNO was determined to be between 0.5 and 40 parts-per-million daily. All therapeutic interventions were standardized. ARDS resulted mainly from sepsis (25 of the 30). During the first 24 h, the hypoxia score increased greatly in patients treated with inhNO + 70.4 mm Hg ( + 59%) versus + 14.2 mm Hg ( + 9.3%) for the control group (p = 0.02), venous admixture decreased from 25.7 to 15.2% in the inhNO group, and from only 19.4 to 14.9% in the control group (p = 0.05). After the first day of therapy no further beneficial effect of inhNO was detected. Forty percent of the patients treated with inhNO were alive and weaned from mechanical ventilation within 30 d after randomization compared with 33.3% in the control group (p = 0.83). The 30-d mortality rate was similar in the two groups; most deaths (11 of 17) were due to multiple organ dysfunction syndrome. This study shows that inhNO, in this population, may improve gas exchange but does not affect mortality.
Initially viewed solely as a surfactant abnormality, identical to that seen in neonatal respiratory distress syndrome (1), acute respiratory distress syndrome (ARDS) in adults is now considered as an inflammatory disorder that transcends pulmonary lesions and includes involvement of the microvasculature in multiple organ systems (2). It is characterized by diffuse radiographic pulmonary infiltrates because of an increased alveolocapillary permeability (3).
The pulmonary lesion is mainly due to an inflammatory interaction between platelets, leukocytes, mononuclear cells, macrophages, and endothelial cells, where oxidative stress is prominent (4). The clinical signs include refractory hypoxemia, mainly because of ventilation/perfusion mismatching, and important right-to-left shunting, high pulmonary arterial pressure often associated with right ventricular dysfunction, noncardiogenic pulmonary edema, and decreased lung compliance with few recruitable lung units (3). If the landmark work of Murray and colleagues (3) helped establish a universal definition of ARDS, the report of the American-European consensus conferences on ARDS (2) outlined the heterogeneity of populations and nonuniformity of therapy, therefore making it difficult to identify outcome predictors.
Nitric oxide (NO) is a vasodilator whose main mechanism of action is the stimulation of soluble guanylate cyclase and the production of cyclic guanosine monophosphate. It also inhibits platelet (5) and leukocyte (6) activation and adhesion and their production of active intermediates (7). As previously demonstrated, local effects of inhaled NO (inhNO) on pulmonary hypertension and consequently right ventricular dysfunction, oxygenation (8), inflammation (9), or pulmonary edema (10) argue for its use in ARDS. Moreover, the extrapulmonary effects of inhNO, i.e., platelet activation (11) and cardiac (12) and renal (13) protective effects could also be helpful for the treatment of patients with ARDS. All these effects are likely to decrease ARDS mortality.
Since the first enthusiastic reports of Rossaint and colleagues (8), and Gerlach and coworkers (14) (respective survival rate of 80 and 100%), and despite the recommendations of the American-European ARDS consensus (2), no study has been appropriately designed to address the clinical outcome of patients with ARDS treated with inhNO. Most of the previous reports on the use of inhNO in ARDS were small case series or crossover designs comparing different therapeutics (8, 12, 14-17). Results from both types of studies were very limited because of selection bias and the absence of a control group followed in parallel. Crossover design also has some major limitations when the condition is not stable in time, and death is frequent. To our knowledge, this is the first report of a randomized controlled trial of patients with ARDS treated with inhNO that addresses its efficacy, not only on gas exchange but also on mortality. The objectives of the trial were to determine: (1) the efficacy of inhNO on lung function; (2) the impact of inhNO on morbidity and mortality; (3) the chances of success and necessary conditions for implementing a larger multicenter trial.
This study was approved by the Human Research and Ethics Committee of the Centre Hospitalier de l'Université de Montréal, and was in accordance with the 1975 Helsinki Declaration. From October 1994 to August 1995, all patients 18 to 75 yr of age suffering from ARDS (the lung injury score [LIS] ⩾ 2.5 of Murray and colleagues) hospitalized in the medical or surgical intensive care units (ICU) were included in the study. Pregnant women, patients with cardiogenic pulmonary edema (pulmonary capillary wedge pressure > 18 mm Hg), or with severe immunodepression from end-stage neoplasia were excluded. Written informed consent was obtained from a close relative. Patients were then randomized to receive either usual care (control group) or usual care plus inhNO (experimental group).
Severity scoring systems (APACHE II [18] and LIS) were calculated for each patient at randomization (Day 0). Patients in both groups were mechanically ventilated following a standardized protocol applied for the fraction of inspired oxygen (Fi O2 ), tidal volume (Vt), ventilatory mode, and positive end-expiratory pressure (PEEP). Sedation, curarization, intravenous perfusion, blood transfusion, parenteral or enteral feeding were also standardized (clinical protocols are available upon request from us). All patients had arterial lines and pulmonary arterial catheters in place for continuous monitoring and blood sampling purposes. Pulse oximetry, end-tidal carbon dioxide tension (Pet CO2 ) were also continuously monitored. Arterial blood gases and pH and pulmonary and systemic hemodynamic parameters were measured at least once every 8 h, whereas venous blood gases, methemoglobinemia, cardiac output, and cardiopulmonary profiles were obtained at least daily.
Therapeutic success was defined as successful weaning from mechanical ventilation with extubation within 30 d after inclusion in the study. Briefly, all patients, whether ventilated with pressure-controlled or conventional ventilatory volumetric SIMV (synchronized intermittent mandatory ventilation) mode were weaned with progressive decrease in SIMV rate supplemented with pressure support. Afterwards, if patients maintained the usual clinical parameters with pressure support ⩽ 10 cm H2O, PEEP ⩽ 5 cm H2O, and Fi O2 ⩽ 0.5 they were extubated. This protocol was applied in a similar manner to all patients in the study. Therapeutic failure was defined as death before 30 d or pursuit of mechanical ventilation (patient always intubated) from Day 31 onwards. Lung function status was assessed by the hypoxia score (HS = PaO2 /Fi O2 ), alveolar dead space (Vda/Vt = 1 − [Pet CO2 /PaCO2 ]), lung compliance (Cl = Vt/[Ppeak − totalPEEP]), and venous admixture [Q˙va/Q˙t = 100 × (Cc O2 − CaO2 )/(Cc O2 − CvO2 )] (PaO2 , PaCO2 : partial pressures of arterial oxygen and carbon dioxide; Ppeak: peak airway pressure; Cc O2 , CaO2 , and CvO2 : capillary, arterial, and venous oxygen contents). Nonresponders to inhNO were defined as patients presenting a ⩽ 20% increase in HS after initial optimal inhNO administration. All patients, responders and nonresponders, were included in the statistical analysis.
Cylinders contained 900 ppm of NO in N2 gas (Air Liquide Ltée., Montréal, PQ, Canada) with NO2 < 5 ppm. The NO/N2 mixture was cyclically injected into the inspiratory line of the mechanical ventilator (7200; Puritan-Bennett Inc., Carlsbad, CA) using an inhNO administration system developed at our institution (19). The fractions of inspired NO (Fi NO) and NO2 (Fi NO2 ) delivered to the patients were measured electrochemically (Polytron NO, NO2; Dräger AG, Lübeck, Germany). The calibration of the electrochemical device was performed at least weekly, and validated with chemiluminescence (CLD 700 AL NO/NOx analyzer; Ecophysics Tecan AG, Dürten, Switzerland).
In the experimental group, the lowest Fi NO that produced the greatest improvement in PaO2 was determined every day (optimal Fi NO = minimal dose with maximal efficacy on PaO2 ). During the determination of optimal Fi NO, no treatment or procedure susceptible of changing the arterial oxygenation or the hemodynamic status (defined as inhNO evaluative parameters) was allowed.
The initial Fi NO was 2.5 ppm. The parameters were collected immediately before (baseline values) and 10 min after introduction of inhNO. The value of Fi NO was then increased stepwise according to the following pattern of concentrations: 5, 10, 20, 30, and up to a maximum of 40 ppm. The decision to increase Fi NO was directed by the observed changes in PaO2 assessed 10 min after the modification of Fi NO. Basically, Fi NO was increased until the increase in PaO2 was smaller than 5% from the previous assessment. Theoretically, if there was no beneficial effect with all doses tested (2.5 to 40 ppm), Fi NO was kept at 5 ppm, but this situation never occurred. Once determined, initial optimal Fi NO was kept unchanged for 24 h.
Every morning Fi NO was decreased stepwise following the same pattern; below 2.5 ppm the two stages were 1 and 0.5 ppm, down to 0 ppm if possible. Similarly, PaO2 was collected 10 min after each modification, and the decrease in Fi NO was stopped when it induced a larger than 5% decrease in PaO2 . In that case the previous Fi NO was kept for 24 h. If the first decrease in Fi NO induced a fall in PaO2 by more than 5%, effects of higher Fi NO were determined stepwise, as previously described.
In the eventuality that no beneficial effects with inhNO was observed for the first 2 d, we had anticipated to withdraw the therapy. Daily optimal Fi NO determination, through regular reverse dose-response assessments, allowed patients to be gradually weaned from inhNO. The patients had the criteria to be weaned from inhNO treatment if they maintained a PaO2 ⩾ 70 mm Hg with Fi O2 ⩽ 0.4 and PEEP ⩽ 8 cm H2O during the daily optimal Fi NO determination at 0 ppm Fi NO for two consecutive days.
After successful weaning, treatment was resumed if the pulmonary status deteriorated. Criteria for reintroduction were: Fi O2 > 0.4, PEEP > 10 cm H2O, and PaO2 ⩽ 60 mm Hg. Initial optimal Fi NO was determined as previously described.
For the comparison between groups, we distinguished two phases to separate the initial effect of inhNO (8, 20) from its remaining effect during prolonged administration. The initial response to inhNO was defined as the difference between the baseline value and the value measured under initial optimal Fi NO. The follow-up effect was assessed by the rate of change from Day 1 to the last day of follow-up. Differences in lung function were determined first by examining the appropriateness of fitting linear regression slope for each individual patient, second by estimating the linear slope for each individual patient, third by weighting the individual slopes according to the precision with which they were estimated, and finally by comparing the difference between the inhNO and control group mean slopes using Student's t test (SAS for Windows™, release 6.11; SAS Institute Inc., Cary, NC). The appropriateness of the linear approximation was determined by adding a quadratic term to the model for an individual patient's lung function and examining whether the addition provided a statistically significant improvement in fit. Because patients could contribute different numbers of observations to the estimation of their respective slopes, not all individual slopes were estimated with the same precision. In order to account for this, individual slopes were weighted inversely proportional to the square of standard error (1/ SE2) when they were combined to obtain an average slope. The therapeutic success rates in each group were compared using a log-rank test. For the primary analysis, an intention to treat approach was used. Those patients who died were assigned the maximum possible length of ventilation, 30 d. Subsequent analysis examined outcomes in the subgroups of patients who remained alive for the duration of the follow-up. Data are expressed as mean ± SE.
Thirty patients with ARDS were randomized, 15 to each of the experimental and control groups. Established ARDS was present in 13 medical and 17 surgical ICU patients. No trauma-induced ARDS was noted during the study period. Twelve patients in the control group, and 13 in the experimental group were septic, and all others recruited resulted from direct lung injury (infectious pneumonia, aspiration, or toxic inhalation). The two groups were similar with regard to most baseline demographic and prognostic variables (Table 1). patients treated with inhNO, however, were on average slightly more sick, with a HS that was lower, and an APACHE II score that was higher, than patients in the control group.
| Control Group (n = 15) | Inhaled NO Group (n = 15) | |||
|---|---|---|---|---|
| Age, yr | 54.8 ± 3.7 | 55.7 ± 3.6 | ||
| Sex, % male | 60.0 | 66.7 | ||
| Smoker, % | 46.6 | 53.3 | ||
| Alcoholism, % | 20.0 | 26.6 | ||
| APACHE II score† | 23.2 ± 1.4 | 27.4 ± 2.6 | ||
| Hypoxia score, mm Hg‡ | 152.1 ± 18.5 | 119.4 ± 13.6 | ||
| LIS§ | 2.86 ± 0.1 | 2.92 ± 0.1 |
The initial optimal Fi NO decreased pulmonary arterial pressure without changing systemic arterial pressure and heart rate (Table 2). Inhaled NO significantly improved the gas exchange parameters: increases in PaO2 by 66.2% (p = 0.0025) and H+ concentration by 4.5% (p = 0.0025); decreases in PaCO2 by 7% (p = 0.0001) and Hco 3 − by 2.8% (p = 0.02). Although Pet CO2 remained unchanged, Vda/Vt and aaPo 2 decreased significantly. The mean initial optimal Fi NO established for the first day was 8.5 ± 2.6 ppm. five of 15 patients were nonresponders to inhNO (increase in HS ⩽ 20%). There was no difference in the initial mean HS between responders and nonresponders (127.7 ± 25.6 versus 118 ± 19.6 mm Hg, respectively). Comparison between groups showed that the initial changes of PaO2 , HS and Q˙va/Q˙t were significantly larger in the experimental group than in the control group (Table 3).
| Baseline†(n = 15) | With Initial Optimal Fi NO(n = 15) | p Value‡ | ||||
|---|---|---|---|---|---|---|
| Ppa, mm Hg‡ | 30.2 ± 1.2 | 26.9 ± 1.3 | 0.0054 | |||
| Psa, mm Hg | 75.1 ± 3.1 | 76.5 ± 3.2 | 0.2067 | |||
| HR, beats/min | 97.9 ± 4.4 | 96.4 ± 4.7 | 0.2851 | |||
| PaO2 , mm Hg | 78.7 ± 3.8 | 130.7 ± 15.7 | 0.0025 | |||
| SaO2 , % | 93.9 ± 0.7 | 97.2 ± 0.5 | 0.0001 | |||
| pHa | 7.36 ± 0.02 | 7.38 ± 0.02 | 0.0025 | |||
| PaCO2 , mm Hg | 43.3 ± 1.4 | 40.1 ± 1.4 | 0.0001 | |||
| Hco 3 −, mmol/L | 24.9 ± 1.2 | 24.2 ± 1.2 | 0.0217 | |||
| Pet CO2 , mm Hg | 31.1 ± 1.4 | 30.6 ± 1.4 | 0.7683 | |||
| Vda/Vt, % | 29 ± 2 | 24 ± 3 | 0.0206 | |||
| aaPo 2, mm Hg | 354.4 ± 31.4 | 305.8 ± 30.9 | 0.0037 | |||
| Initial Fi NO, ppm | 0 | 8.5 ± 2.6 |
| Baseline† | Difference between Day 1 and Baseline | Average Daily Change (Linear Slope) from Day 1 | ||||
|---|---|---|---|---|---|---|
| PaO2 , mm Hg | ||||||
| Control group | 99.1 ± 8.3 | −6.2 ± 10.7 | −1.01 ± 0.3 | |||
| Inhaled NO group | 80.5 ± 4.8 | +23.3 ± 6.9 | −1.2 ± 0.4 | |||
| p Value‡ | 0.03 | 0.72 | ||||
| HS, mm Hg | ||||||
| Control group | 152.1 ± 18.5 | +14.2 ± 18.1 | +1.2 ± 1.5 | |||
| Inhaled NO group | 119.4 ± 13.6 | +70.4 ± 13.4 | −2.8 ± 1.5 | |||
| p Value | 0.02 | 0.06 | ||||
| PEEP, cm H2O | ||||||
| Control group | 10.6 ± 1.7 | +1 ± 0.5 | −0.1 ± 0.1 | |||
| Inhaled NO group | 10.2 ± 0.7 | +0.6 ± 0.7 | −0.2 ± 0.1 | |||
| p Value | 0.68 | 0.36 | ||||
| CL, ml/cm H2O | ||||||
| Control group | 29.9 ± 3.6 | −0.9 ± 1.6 | −0.5 ± 0.1 | |||
| Inhaled NO group | 31.8 ± 2.9 | +0.2 ± 2.7 | −0.2 ± 0.1 | |||
| p Value | 0.73 | 0.25 | ||||
| Q˙ va/Q˙ t, % | ||||||
| Control group | 19.4 ± 2.1 | −4.5 ± 2.2 | +0.05 ± 0.2 | |||
| Inhaled NO group | 25.7 ± 3.2 | −10.5 ± 2.1 | +0.07 ± 0.2 | |||
| p Value | 0.05 | 0.83 |
Excluding the initial effect, we did not observe any difference between groups. There was not sufficient evidence to support the use of a quadratic model for any of the measures of lung function considered (the proportion of patients with significant quadratic terms never exceeded 20%). Accordingly, for each patient we characterized the change in lung function over the follow-up period by the slope of the corresponding linear regression of lung function on time. As shown in Table 3, the mean weighted linear slopes from Day 1 onward for PEEP, Cl, and Q˙va/Q˙t were not different between groups; there was some evidence (p = 0.06) of a difference in the change of HS, with a tendency of greater decline in the inhNO-treated group than in the control group. It should be noted that the estimated mean weighted linear slopes were sometimes highly variable between individual patients, e.g., for HS in the inhNO group, comprising essentially an equal number of positive and negative individual slopes. The mean Fi NO used during the study, based on optimal dosage determination, was 5.6 ± 1.8 ppm. The mean duration of inhNO treatment was 8.1 ± 1.3 d (range: 28 to 453 h), Fi NO2 was always ⩽ 1 ppm, and excessive methemoglobinemia was never detected.
The 30-d mortality and the duration of mechanical ventilation were almost identical in the two groups: nine of 15 deaths and 22.3 ± 2.5 d of ventilation in the inhNO group versus eight of 15 deaths and 24.1 ± 2.5 d in the control group. A majority of the deaths (11 of 17) occurred from multiple organ dysfunction syndrome (MODS). Although the subgroup of survivors treated with inhNO showed a 20% reduction in the duration of mechanical ventilation when compared with the control group (10.8 ± 1.2 versus 12.8 ± 4.2 d, respectively), the difference was not statistically significant (p = 0.44). The global evolution of therapeutic success was not different between the two groups (p = 0.83) (Figure 1). In the experimental group, the final therapeutic success rate was slightly higher (40%) and reached earlier (at Day 15) than in the control group (33.3% at Day 30). Of the five patients of both groups with direct ling-injury-induced ARDS only one died, in the control group. Consequently, the therapeutic success rate of the remaining patients with sepsis-induced ARDS was 28% (30.8% in the inhNO, and 25% in the control group). Four of five inhNO nonresponders died, and the therapeutic success rate in inhNO responders was 50%.
Fig. 1. Therapeutic success rate evolution of control and experimental (inhaled NO) groups. Therapeutic success was defined as successful weaning from mechanical ventilation with extubation within 30 d after inclusion in the study. There was no evidence of difference between the two groups (p = 0.83).
[More] [Minimize]This is the first report of a randomized controlled trial of patients with ARDS treated with inhNO that addresses these issues. Small sample size, heterogeneous populations and treatments, as well as selection bias, plagued previous studies on the effect of inhNO in patients with ARDS. Moreover, none of them used a control group without inhNO followed in parallel except Chollet-Martin and colleagues (9) whose main objective was not the survival rate. Several of these studies carried out a crossover design with prostacyclin (8, 12, 15) or almitrine (16, 17) to study the effect of inhNO on hypoxemia. This design, however, fails to address important clinical outcomes such as survival or weaning and is very limited because of the ARDS instability in time. The lack of consistency in previous studies could result from the high variety of ARDS etiologies, the large Fi NO (10 ppb [20] to 128 [21] ppm) and age (1 [15] to 81 [22] yr) ranges. Most of the investigators used a unique Fi NO dose, which, in our opinion, does not optimize treatment. Finally, several studies used concomitant treatments such as ECMO (8, 12, 14, 20, 23), permissive hypercapnia (22, 24, 25), or vasoactive drugs (16, 21, 25, 26), which makes it difficult to compare the outcome. In our trial, the population was selected on strict criteria and received uniform standardized care for their conditions. Random allocation of the intervention as well as strict objective assessment of the parameters ensured absence of bias.
Our results confirm those of previous studies (15, 20-22, 26, 27) in so far as showing that inhNO initially exerts a moderate pulmonary vasodilatory effect that is accompanied by an improvement in alveolocapillary gas exchange and an absence of clinical systemic hemodynamic effects (Tables 2 and 3). The beneficial effect resulting in improved oxygenation is likely related to the redistribution of blood flow from unventilated shunted areas to ventilated but under perfused areas, the so- called “steal phenomena” (16, 26-28). Unlike that in a study of patients with chronic obstructive pulmonary disease (29), no negative response to introduction of inhNO was observed in our study. By dilating some constricted pulmonary vessels in ventilated lung areas, inhNO improved the high ratio ventilation/perfusion inequality, thereby reducing aaPo 2, and Vda/ Vt. As a consequence, PaCO2 was slightly but significantly reduced. In our study, Pet CO2 was unchanged; other investigators have similarly found either no increase (23, 27) or only a slight (1 to 3 mm Hg) increase (21, 23) in this parameter. The effect of inhNO over time in comparison with a control group has never been published. The initial effects on HS and Q˙va/Q˙t (Table 3) were significantly greater in the experimental group than in the control group. However, after the initial period, there was no evidence of continued improvement in the experimental group or in the control group. There was no significant difference in duration of mechanical ventilation and mortality, and, consequently, the therapeutic success rate was similar in both groups. The slight trend of inhNO improvement through the duration of mechanical ventilation observed with the subgroup of survivors is difficult to interpret. It could represent a real effect or be a product of selection bias.
The contrast between a strong positive initial effect on lung function and the absence of effect on global mortality is striking and may yield different explanations. As noted above, a slight disadvantage on baseline severity scoring systems and lung status was observed in the experimental group. This difference, however, is not likely to explain the absence of survival difference because there was no correlation between the severity of initial scoring systems and the 30-d mortality. A multivariate model, adjusted for the initial severity score, did not change the results. Our results show that after the first day the two groups presented similar evolutions, suggesting that both groups reached the same maximal level of possible improvement, but that patients treated with inhNO did it more quickly. Therefore, inhNO did not change the general health status, which was already profoundly altered (mean APACHE II score = 27.4) when patients were included (established ARDS). Our results are compatible with the fact that the death during the acute phase of ARDS is usually attributable to the underlying illness or injury (30), whereas later deaths are mainly due to MODS (31), and they corroborate the comments of Wenstone and Wilkes (32) that new therapies directed solely at treating the lung will be unlikely to significantly reduce the mortality from what is essentially an inflammatory systemic disease.
In this context one may see the evolution of HS over time as the effect of optimal standard ventilation whose effectiveness is limited by the impaired lung condition; inhNO might help reach this maximum attainable level, without transforming the respiratory function or the final prognosis. It is possible that earlier treatment with inhNO could be more effective on mortality, and ARDS may be easier to reverse (33), or that inhNO administered to patients with direct lung-injury- induced ARDS (without MODS) may also have a positive effect on mortality as well. In the studies done by Rossaint and colleagues (8) and Gerlach and coworkers (14), the majority of patients had ARDS resulting from direct lung injury, and the survival rate with inhNO was high (11 of 13). In our study, the number of patients so affected was small (n = 5) and the prognosis was good in both groups: two of two, and two of three, respectively, in the inhNO and control groups. We also found that nonresponders to inhNO (initial increase in HS ⩽ 20%) had a very poor prognosis (four of five deaths). All these patients, however, were treated because their HS improved by more than 5% with the therapy. The lack of a demonstrable effect on mortality does not imply that administration of inhNO is worthless (34). The rapid improvement in lung function in comparison with the control group is a positive element that may facilitate ventilatory support; hence, decrease iatrogenic pulmonary pathology. This aspect supports the observation made by Petros and colleagues (34) that mortality is not a good criterion to assess the role of a new therapeutic modality in the ICU, and that reducing morbidity is a more adequate achievable end point. Eventually, the additive effects of a number of therapies decreasing morbidity in patients with ARDS may lead to a decrease in mortality (25). It has been shown that the overall mortality has lessened in ARDS, although no single therapeutic approach improved it (35).
Our study confirms the initial efficacy of inhNO on lung function but does not show any significant difference between groups after the first day of follow-up. We observed a more rapid resolution of pulmonary changes in blood gas criteria in ARDS, which was not followed by beneficial effects on lung function, duration of mechanical ventilation, and mortality. Although our sample was representative of a population with sepsis-induced established ARDS resulting in MODS, this pilot study suggests that demonstrating an effect of inhNO on ARDS mortality in this population would be difficult to achieve even with a large multicenter trial. In these conditions, we suggest that further studies should focus on early treatment (when the condition is more likely to be reversible) and on the use of inhNO on selected populations such as patients with ARDS induced by direct lung injury or those responsive to the therapy whatever the etiology. These populations should benefit the most from the use of inhNO with a putative effect not only on gas exchange but also on mortality.
The writers wish to thank Dr. F. Donati, Chairman of the Anesthesia Department of Université de Montréal, for his support, Drs. L. Roux, G. Hellou, and A. Denault for their participation in clinical trial and constructive comments, and Drs. G. Czaika and N. G. Hartman for their help in editing the manuscript. They are also indebted to the nursing and respiratory therapy staff of the medical and surgical ICUs, and all other health professionals of Centre Hospitalier de l'Université de Montréal, Campus Notre Dame for their invaluable collaboration, in particular, Mrs. S. Charneau, N. Rondeau, M. Boivin, Dr. L. Dubé, Mr. R. Carrier, and R. Lapointe.
Supported by Grant MRC-MA 12425 from the Medical Research Council of Canada, and by a Burroughs Wellcome Inc. bursary from the Canadian Anaesthetists' Society.
| 1. | Ashbaugh D. G., Bigelow D. B., Petty T. L., Levine B. E.Acute respiratory distress in adults. Lancet21967319323 |
| 2. | Bernard G. R., Artigas A., Brigham K. L., Carlet J., Falke K., Hudson L., Lamy M., Legall J. R., Morris A., Spragg R.The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am. J. Respir. Crit. Care Med.1491994818824 |
| 3. | Murray J. F., Matthay M. A., Luce J. M., Flick M. R.An expanded definition of the adult respiratory distress syndrome. Am. Rev. Respir. Dis.1381988720723 |
| 4. | Quinlan J. G., Evans T. W., Gutteridge J. M. C.Oxidative damage to plasma proteins in adult respiratory distress syndrome. Free Radic. Res.201994289298 |
| 5. | Radomski M. W., Palmer R. M. J., Moncada S.An l-arginine: nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. U.S.A.57199051935197 |
| 6. | Kubes P., Granger D. N.Nitric oxide modulates microvascular permeability. Am. J. Physiol.2621992H611H615 |
| 7. | Clancy R. M., Leszczynska-Piziak J., Abramson S. B.Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on NADPH oxidase. J. Clin. Invest.90199211161121 |
| 8. | Rossaint R., Falke K. J., López F. A., Slama K., Pison U., Zapol W. M.Inhaled nitric oxide for the adult respiratory distress syndrome. N. Engl. J. Med.3281993399405 |
| 9. | Chollet-Martin S., Gatecel C., Kermarrec N., Gougerot-Pocidalo M. A., Payen D. M.Alveolar neutrophil functions and cytokine levels in patients with the adult respiratory distress syndrome during nitric oxide inhalation. Am. J. Respir. Crit. Care Med.1531996985990 |
| 10. | Benzing A., Geiger K.Inhaled nitric oxide lowers pulmonary capillary pressure and changes longitudinal distribution of pulmonary vascular resistance in patients with acute lung injury. Acta Anaesthesiol. Scand.381994640645 |
| 11. | Samama C. M., Diaby M., Fellahi J. L., Mdhafar A., Eyraud D., Arock M., Guillosson J. J., Coriat P., Rouby J. J.Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology8319955665 |
| 12. | Rossaint R., Slama K., Steudel W., Gerlach H., Pappert D., Veit S., Falke K.Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome. Intensive Care Med.211995197203 |
| 13. | Troncy E., Francœur M., Salazkin I., Yang F., Charbonneau M., Leclerc G., Vinay P., Blaise G. A.Extra-pulmonary effects of inhaled nitric oxide in swine with and without phenylephrine. Br. J. Anaesth.791997631640 |
| 14. | Gerlach H., Pappert D., Lewandowski K., Rossaint R., Falke K. J.Long-term inhalation with evaluated low doses of nitric oxide for selective improvement of oxygenation in patients with adult respiratory distress syndrome. Intensive Care Med.191993443449 |
| 15. | Walmrath D., Schneider T., Schermuly R., Olschewski H., Grimminger F., Seeger W.Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med.1531996991996 |
| 16. | Wysocki M., Delclaux C., Roupie E., Langeron O., Liu N., Herman B., Lemaire F., Brochard L.Additive effect on gas exchange of inhaled nitric oxide and intravenous almitrine bismesylate in the adult respiratory distress syndrome. Intensive Care Med.201994254259 |
| 17. | Lu Q., Mourgeon E., Law-Koune J. D., Roche S., Vezinet C., Abdennour L., Vicaut E., Puybasset L., Diaby M., Coriat P., Rouby J. J.Dose-response curves of inhaled nitric oxide with and without intravenous almitrine in nitric oxide-responding patients with acute respiratory distress syndrome. Anesthesiology831995929943 |
| 18. | Knaus W. A., Draper E. A., Wagner D. P., Zimmerman J. E.APACHE II: a severity of disease classification system. Crit. Care Med.131985818829 |
| 19. | Dubé L., Francœur M., Troncy E., Carrier R., Blaise G.Comparison of two administration techniques of inhaled nitric oxide on nitrogen dioxide production. Can. J. Anaesth.421995922927 |
| 20. | Gerlach H., Rossaint R., Pappert D., Falke K. J.Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur. J. Clin. Invest.231993499502 |
| 21. | Young J. D., Brampton W. J., Knighton J. D., Finfer S. R.Inhaled nitric oxide in acute respiratory failure in adults. Br. J. Anaesth.731994499502 |
| 22. | Puybasset L., Stewart T., Rouby J. J., Cluzel P., Mourgeon E., Belin M. F., Arthaud M., Landault C., Viars P.Inhaled nitric oxide reverses the increase in pulmonary vascular resistance induced by permissive hypercapnia in patients with acute respiratory distress syndrome. Anesthesiology80199412541267 |
| 23. | Rossaint R., Gerlach H., Schmidt-Ruhnke H., Pappert D., Lewandowski K., Steudel W., Falke K.Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest107199511071115 |
| 24. | Wysocki M., Vignon P., Roupie E., Humbert M., Adnot S., Lemaire F., Brochard L.Improvement in right ventricular function with inhaled nitric oxide in patients with the adult respiratory distress syndrome (ARDS) and permissive hypercapnia (abstract). Am. Rev. Respir. Dis.1471993A350 |
| 25. | Levy B., Bollaert P. E., Bauer P., Nace L., Audibert G., Larcan A.Therapeutic optimization including inhaled nitric oxide in adult respiratory distress syndrome in a polyvalent intensive care unit. J. Tr. Inj. Inf. Crit. Care381995370374 |
| 26. | Bigatello L. M., Hurford W. E., Kacmarek R. M., Roberts J. D., Zapol W. M.Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress. Anesthesiology801994761770 |
| 27. | Puybasset L., Rouby J. J., Mourgeon E., Cluzel P., Souhil Z., Law-Koune J. D., Stewart T., Devilliers C., Lu Q., Roche S., Kalfon P., Vicaut E., Viars P.Factors influencing cardiopulmonary effects of inhaled nitric oxide in acute respiratory failure. Am. J. Respir. Crit. Care Med.1521995318328 |
| 28. | Cioffi W. G., Ogura H.Inhaled nitric oxide in acute lung disease. New Horiz.319957385 |
| 29. | Barberà J. A., Roger N., Roca J., Rovira I., Higenbottam T. W., Rodriguez-Roisin R.Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet3471996436440 |
| 30. | Artigas, A., J. Carlet, J. R. Le Gall, C. L. Chastang, L. Blanch, and R. Fernandez. 1991. Clinical presentation, prognostic factors, and outcome of ARDS in the European Collaborative Study 20(1985–1987): a preliminary report. In W. M. Zapol and F. Lemaire, editors. Adult Respiratory Distress Syndrome. Marcel Dekker, New York. 37–63. |
| 31. | Montgomery A. B., Stager M. A., Carrico C. J., Hudson L. D.Causes of mortality in patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis.1321985485489 |
| 32. | Wenstone R., Wilkes R. G.Clinical management of ARDS. Br. J. Anaesth.721994617619 |
| 33. | Lowson S. M., Rich G. F., McArdle P. A., Jaidev J., Morris G. N.The response to varying concentrations of inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesth. Analg.821996574581 |
| 34. | Petros A. J., Marshall J. C., Van Saene H. K.Should morbidity replace mortality as an endpoint for clinical trials in intensive care? Lancet3451995986987 |
| 35. | Morris A. H., Wallace C. J., Menlove R. L., Clemmer T. P., Orme J. F., Weaver L. K., Dean N. C., Thomas F., East T. D., Pace N. L., Suchyta M. R., Beck E., Bombino M., Settig D. F., Bohm S., Hoffmann B., Becks H., Butler S., Pearl J., Rasmusson B.Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am. J. Respir. Crit. Care Med.1491994295305 |
Dr. Troncy is the recipient of grants from Faculté des Études Supérieures, Université de Montréal, Rhône-Alpes region Eurodoc program, and Heart and Stroke Foundation of Canada Research Traineeship Program.
